| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() FDA Approves Prandin, New Oral Treatment For Type II Diabetes BAGSVAERD, DENMARK -- December 23, 1997 -- The United States Food and Drug Administration (FDA) has approved Novo Nordisk A/S’s Prandin(TM) (repaglinide), a new agent for treatment of Type II diabetes. Prandin is the first approved product in a new chemical class (meglitinide class) of orally-administered drugs for the treatment of Type II diabetes and was developed to manage meal-related (prandial) glucose loads. It is different from other oral anti-diabetic agents in structure and clearance. Its quick onset and short duration of action concentrates its effect around meal time glucose load, which is important to the treatment of Type II diabetes. If a meal is skipped, so is the Prandin tablet; if a meal is added during the day, a tablet is added for that meal. Prandin stimulates insulin secretion from the beta cells of the pancreas by binding to sites on the beta cell. Prandin is minimally excreted by the kidney, which may be an advantage for patients (often elderly) who often suffer from decreased kidney function. The agent is in-licensed by Novo Nordisk for worldwide development and marketing. The product trade name outside the U.S. will be NovoNorm .
|